Dockets Management Br	canch	΄ Τ	Date: 8 27 99
The <b>Food</b> and Drug Administration,			
	Human Services, Rm. 1-23		
12420 <b>Parklawn</b> Dr. <b>Rockville,</b> MD 20857			
	ition to Have <i>Eternity <b>eau</b> de <b>p</b>e</i>	arfum declared "Misbrandec	/// 20 255
Dear Sir or Madam:		,	9 SEP -3 A11:03
In May 1999, the Environmental <b>Health</b> Network (EHN) submitted the above petition to have Calvin Klein's <i>Eternity</i> eau de parfum declared "misbranded." I am writing because I fully support this petition and request that the FDA give it careful <b>attention with</b> regard to your regulations 21CFR Sec. <b>740.1</b> , <b>21CFR</b> Sec. 740.2, and			
_	lation 21CFR Sec. 740.10 states		en og sommer en
stantiated for safety substantiated prior to	I in a <b>cosmetic</b> product and eac prior to <b>marketing</b> . Any such o marketing is misbranded un	ingredient or product whose	safety is not adequately
the principal display	panel: ety of this product has not bee	on determined "	
· ·	Fisher Pan / Programmer Committee Co	graphs sector	Process of the Process of the Control of the Contro
As the <b>petition</b> shows, Et tiated. There is no warnin	ernity contains toxic ingredien ig label on its packaging.	its and ingredients whose sa	fety have not been substan-
	now the <b>status</b> of safety testin		
	and our families from toxic chragrance materials have only		
products are safe to use in	n any setting and are surprised	d when people complain.	
peopie, including: people es. Children are particular parents, caregivers and te	with asthma, chemical sensitively vulnerable to toxic chemical sensitively vulnerable to toxic chemical achers. When I am exposed to	ivities, chronic fatigue, and als found in products purch fragrance products I can express the second contracts of the second	other environmental illness-ased and <b>used</b> by their
	n the chemical fragrance produ	uct I encounter:	n 56
0 asthma	Company - Walter Company (1974)	incoherence	nausea
anaphylaxis',	ear pain	incontinence	nose bleeds
anxiety, restlessness breathing difficulty	e c z e m a eyes, watery or dry	☐ irritability ☐ joint aches	☐ rashes ☐ seizures
bronchitis	fatigue'	0 laryngitis	short-term mem. loss
0, can't concentrate	flushing	lethargy	0 sinusitis
0. coughing	☐ headaches	0 lymph nodes swell	sneezing
0 depression	heart beat irregularity	0 mood swings	sores, skin/mouth
disorientation	0 hives		s 0 swallowing difficulty
dizziness	0 hypertension	nasal congestion	🗖 tinnitus
<b>o</b> ther:	#据查施数: * * * * * * * * * * * * * * * * * * *		Past.
Please act on behalf of t	the millions, of people who ha	ve suffered physical illness :	and injury <b>resulting</b> from
fragrance exposure at wor	k, at <b>school and</b> in social settir	ngs. These toxic. chemicals a	ct as powerful barriers to
	and chemical sensitivities. T	'oxic chemicals in fragrance	s have already ruined
countless lives. Thank you	ı.	1.	- <u>-</u>
Sincerely,			
yourname Pleis	<u>h</u>	_	
yourname Juanhor Lone Sugnarion CT D 6 + 30			
addless; city/st/zip QQP-1340			
Newsletters and everyone who feels people have a right to know, please copy, share, tell your friends and WRITE the FDAtoday!			

first, fold down





Attn: 99P-1340|CP1

Dockets Management Branch
The Food and Drug Administration
Department of Health & Human Services, Rm. 1-23
12420 Parklawn Dr.
Rockville, MD 20857

haldlindalalalalandala

second, fold up